Search Result

Results for "

T-cell leukemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Itk (2) Akt (3) Antibiotic (1) Apoptosis (21) Aurora Kinase (1) Bacterial (3) Bcr-Abl (1) Btk (3) c-Myc (1) Calcium Channel (2) Casein Kinase (6) CCR (1) CD1 (1) CD19 (3) CD2 (1) CD28 (1) CD3 (6) CD47 (1) CDK (2) CXCR (4) Dipeptidyl Peptidase (1) Discoidin Domain Receptor (1) Drug Derivative (1) Drug Metabolite (1) Endogenous Metabolite (1) Environmental Pollutants (2) Epigenetic Reader Domain (1) ERK (1) Eukaryotic Initiation Factor (eIF) (3) Fc Receptor (FcR) (1) FLT3 (1) Fungal (1) Galectin (1) Glucocorticoid Receptor (1) GSK-3 (2) HDAC (1) Histamine Receptor (4) Histone Acetyltransferase (1) Histone Demethylase (5) Histone Methyltransferase (1) HIV (1) HIV Integrase (1) HSP (3) HSV (1) IFNAR (10) IGF-1R (1) Interleukin Related (10) JAK (3) LAG-3 (3) LPL Receptor (2) Microtubule/Tubulin (4) Mitochondrial Metabolism (2) Molecular Glues (4) mRNA (1) NF-κB (4) Notch (3) Nucleoside Antimetabolite/Analog (2) Orexin Receptor (OX Receptor) (1) P-glycoprotein (1) p38 MAPK (1) PACAP Receptor (2) Parasite (1) PARP (2) PD-1/PD-L1 (3) Phosphatase (1) PI3K (8) PROTACs (3) Reactive Oxygen Species (ROS) (3) Reference Standards (8) SARS-CoV (2) Sec61 (2) Src (3) STAT (7) TGF-beta/Smad (1) Thrombopoietin Receptor (1) TNF Receptor (11) Toll-like Receptor (TLR) (1) Topoisomerase (1) Transmembrane Glycoprotein (2) γ-secretase (1)
By Research Areas:	Cancer (85) Cardiovascular Disease (3) Endocrinology (2) Infection (10) Inflammation/Immunology (33) Metabolic Disease (3) Neurological Disease (2)
Oligonucleotides:	CAR-T (1) CpG ODNs (2) mRNA (1) Antisense Oligonucleotides (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Oligonucleotides

Targets Recommended: Itk Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19356

Rocaglamide 25+ Cited Publications Roc-A	NF-κB HSP Eukaryotic Initiation Factor (eIF)	Inflammation/Immunology Cancer
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia .

HY-P9963

Blinatumomab 2 Publications Verification bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-156730

KT-333	Molecular Glues STAT	Cancer
KT-333 is a molecular glues that degrades STAT3 protein. KT-333 mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) .

HY-12279

Umbralisib 5 Publications Verification TGR-1202; RP5264	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib can be used for haematological malignancies reseach .

HY-P99014

Cusatuzumab 1 Publications Verification ARGX-110	Fc Receptor (FcR) NF-κB	Inflammation/Immunology Cancer
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .

HY-108691

PF-06465469 2 Publications Verification	Itk Btk CXCR PD-1/PD-L1 LAG-3	Cancer
PF-06465469 is a covalent inhibitor of ITK with an IC₅₀ of 2 nM. PF-06465469 also inhibits BTK. PF-06465469 inhibits cell migration in response to CXCL12. PF-06465469 decreases PD-1 and LAG-3 expression. PF-06465469 can be used to study leukemia and T-cell lymphoma .

HY-13701

Nelarabine 3 Publications Verification 506U78; GW 506U78; Nelzarabine	Nucleoside Antimetabolite/Analog Apoptosis	Cancer
Nelarabine (506U78) is a nucleoside analogue and can be used for the research of T cell acute lymphoblastic leukemia (T-ALL) .

HY-109108A

Valemetostat tosylate 5 Publications Verification DS-3201 tosylate	Histone Methyltransferase	Cancer
Valemetostat (DS-3201) tosylate, a first-in-class EZH1/2 dual inhibitor with IC₅₀ values ＜10 nM. Valemetostat tosylate can be used for the research of relapsed/refractory peripheral T-cell lymphoma .

HY-P99521

Vibecotamab XmAb14045	CD3	Inflammation/Immunology Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .

HY-153084A

CD19 CAR mRNA (Human) 1 Publications Verification	mRNA CD19	Cancer
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .

HY-137471

RBPJ Inhibitor-1 5+ Cited Publications RIN1	Notch	Cancer
RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation .

HY-150725

ODN 1585	IFNAR TNF Receptor	Infection Inflammation/Immunology Cancer
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-160041A

Olaptesed pegol sodium NOX-A12 sodium	CXCR	Cancer
Olaptesed pegol (NOX-A12) sodium is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia .

HY-160041

Olaptesed pegol NOX-A12	CXCR	Cancer
Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia .

HY-176244

KI-TOX-A3	Histone Acetyltransferase	Cancer
KI-TOX-A3 is a TOX protein-protein interaction inhibitor that blocks the TOX-KAT7 protein-protein interaction with an IC₅₀ of 0.51 μM. KI-TOX-A3 induces proteasomal degradation of TOX, restores KAT7-mediated H3K14 acetylation, reverses exhaustion of CD8 ⁺ T cells, and inhibits the proliferation of T cell acute lymphoblastic leukemia (T-ALL) cells. KI-TOX-A3 shows promise for use in studies of hematological malignancies such as T-ALL .

HY-P99910

Eluvixtamab AMG-330	CD3 Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and CD3 on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia .

HY-124447

BTYNB	IGF-1R c-Myc Apoptosis TGF-beta/Smad	Cancer
BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC₅₀ of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma .

HY-13660

Mocravimod hydrochloride 2 Publications Verification KRP-203	LPL Receptor Reactive Oxygen Species (ROS) Akt GSK-3 JAK STAT	Metabolic Disease Inflammation/Immunology Cancer
Mocravimod (hydrochloride) is an orally active sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod (hydrochloride) preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod (hydrochloride) significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod (hydrochloride) retains T cell effector function. Mocravimod (hydrochloride) can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .

HY-109038

Mocravimod 2 Publications Verification KRP-203 free base	LPL Receptor Reactive Oxygen Species (ROS) Mitochondrial Metabolism Akt GSK-3 JAK STAT	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Mocravimod (KRP-203 free base) is a sphingosine-1-phosphate receptor (S1PR) modulator that blocks the signal required by T cells to egress from lymph nodes and other lymphoid organs. Mocravimod preferentially binds to S1PR1 over S1PR2 and S1PR3 in cardiomyocytes. Mocravimod significantly lowered the concentration of reactive oxygen species (ROS), prevented mitochondrial permeability transition pore opening, boosted mitochondrial membrane potential (MMP), and increased phosphorylation of AKT, EKR, GSK-3β, JAK2, and STAT3. Mocravimod retains T cell effector function. Mocravimod can be used for the study of acute myelogenous leukemia, diabetes and Myocardial Ischemia-Reperfusion Injury (MIRI) .

HY-149760

PVD-06	PROTACs Phosphatase IFNAR STAT	Cancer
PVD-06 is a selective PROTAC PTPN2 degrader with a DC₅₀ of 217 nM (selectivity index >60-fold over PTP1B). PVD-06 induces PTPN2 degradation via a VHL-, ubiquitin, and proteasome-dependent pathway. PVD-06 can promote T cell activation and amplify IFN-γ-mediated anticancer activity. PVD-06 can be used to further investigate PTPN2 in diseases such as leukemia and melanoma . (Pink: PTPN2 ligand (HY-168691), Black: linker (HY-B0236), Blue: VHL ligand (HY-112078)).

HY-P99253

Mogamulizumab 1 Publications Verification KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-W014118

α-Hexylcinnamaldehyde	Environmental Pollutants	Inflammation/Immunology Cancer
α-Hexylcinnamaldehyde is an O-acetyltransferase (OAT) inhibitor. α-Hexylcinnamaldehyde inhibits OAT-mediated bioactivation of nitroarene mutagens, exerts antimutagenic activity through demutagenic and bioantimutagenic mechanisms, and interferes with ATP-binding cassette (ABC) transporter function to reduce substrate efflux. α-Hexylcinnamaldehyde alters membrane permeability, fluidizes phospholipid membranes, exerts antioxidant effects, and enhances the antiproliferative effect of Doxorubicin on human cancer cells. α-Hexylcinnamaldehyde can be used in the research of colorectal adenocarcinoma, T-cell leukemia, and multidrug-resistant cancers .

HY-P99916

Emirodatamab AMG-427	FLT3 CD3 TNF Receptor	Inflammation/Immunology Cancer
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of *acute myeloid leukemia* (AML)** cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .

HY-12279C

Umbralisib hydrochloride 5 Publications Verification TGR-1202 hydrochloride; RP5264 hydrochloride	PI3K Casein Kinase	Cancer
Umbralisib (TGR-1202) hydrochloride is an orally active, potent and selective dual PI3Kδ and casein kinase-1-ε (CK1ε) inhibitor, with EC₅₀ of 22.2 nM and 6.0 μM, respectively. Umbralisib hydrochloride exhibits unique immunomodulatory effects on chronic lymphocytic leukemia (CLL) T cells. Umbralisib hydrochloride can be used for haematological malignancies reseach .

HY-150725C

ODN 1585 sodium	TNF Receptor IFNAR	Infection Inflammation/Immunology Cancer
ODN 1585 sodium is a potent inducer of IFN and TNFα production. ODN 1585 sodium is a potent stimulator of NK (natural killer) function. ODN 1585 sodium increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 sodium induces regression of established melanomas in mice. ODN 1585 sodium can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 sodium can be used as a vaccine adjuvant .

HY-119715

AG-012986	CDK Apoptosis	Inflammation/Immunology Cancer
AG-012986 is a pan-CDK inhibitor with K_i values of 44 nM (CDK1), 9.2 nM (CDK4), 94 nM (CDK2), and IC50 values of 22 nM (CDK5), 4 nM (CDK9). AG-012986 causes apoptosis of T-cells by targeting upstream kinases in the p38 Mitogen-activated protein kinase (MAPK) pathway and impairing cellular survival. AG-012986 induces cell cycle arrest, retinoblastoma protein hypophosphorylation, and reduces K_i-67 expression. AG-012986 exerts antiproliferative activity in tumor cells, demonstrates antitumor efficacy in human xenograft models, and causes retinal and peripheral neurotoxicity, plus immune cell toxicity. AG-012986 can be used for the research of colon carcinoma, non-small cell lung carcinoma, lung carcinoma, breast carcinoma, ovarian tumor, pancreatic carcinoma, osteosarcoma, lymphoma, leukemia, retinotoxicity .

HY-168022

CAM2602 1 Publications Verification	Aurora Kinase	Cancer
CAM2602 is an orally active Aurora A-TPX2 protein−protein interaction inhibitor with a human K_d of 19 nM for Aurora A. CAM2602 increases the proportion of PH3 positive cells while reducing P-T288 Aurora A levels. CAM2602 arrests tumor xenograft growth in mice. CAM2602 can be used for the research of cancer, such as acute T cell leukemia .

HY-P11288

ANT308	PACAP Receptor Apoptosis	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P11288A

ANT308 TFA	PACAP Receptor Apoptosis	Cancer
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-13305

MK-2048	HIV HIV Integrase Apoptosis PARP	Infection
MK-2048 is a HIV-1 and HIV-1 integrase inhibitor. MK-2048 shows selective activity against HTLV-1-infected cells and retained potency against HIV-1 variants. MK-2048 induces apoptosis, inhibits cell growth, reduces proviral loads, and blocks HTLV-1 transmission and immortalization. MK-2048 can be used for the research of HIV-1 infection .

HY-171178

DK2403	p38 MAPK	Cancer
DK2403 (compound 25) is a MAP2K7 inhibitor (IC₅₀= 0.01 μM). DK2403 can effectively inhibit MAP2K7 without significantly disrupting the larger kinase group and can be used to study childhood T-cell acute lymphoblastic leukemia .

HY-B0971

Pheniramine maleate Prophenpyridamine maleate; Tripoton maleate	Histamine Receptor Apoptosis	Inflammation/Immunology Endocrinology
Pheniramine (Prophenpyridamine; Tripoton) maleate is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine maleate displays antitumor effect and induces leukemia cells apoptosis. Pheniramine maleate is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .

HY-169789

PKN3-IN-1	PI3K	Metabolic Disease Cancer
PKN3-IN-1 (compound 16) inhibits PKN3 (serine/threonine protein kinase 3) and GAK (cyclin G-associated kinase) with IC₅₀ of 0.014 μM and K_i of 0.0044 μM respectively. PKN3-IN-1 is a potential tool compound to study the cell biology of PKN3 and its role in pancreatic and prostate cancer and T-cell acute lymphoblastic leukemia .

HY-13743

Roquinimex Linomide; FCF89; ABR212616	TNF Receptor Interleukin Related IFNAR	Neurological Disease Inflammation/Immunology Cancer
Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis .

HY-P2302

Defensin HNP-3 human	Antibiotic Bacterial Fungal	Infection Inflammation/Immunology Cancer
Defensin HNP-3 human is an α-defensin stored in the azurophilic granules of human neutrophils. Defensin HNP-3 human exerts broad-spectrum bactericidal, antifungal and antiviral activities mainly by forming bacterial membrane pores, and acts as a chemoattractant for monocytes and T cells. Defensin HNP-3 human maintains epithelial integrity to support periodontal tissue homeostasis, and exerts concentration-dependent effects on epithelial cell proliferation, adhesion and bacterial adhesion. Defensin HNP-3 human targets solid tumors and leukemia by inducing single-strand DNA breaks and membrane permeabilization in tumor cells via electrostatic binding and pore formation. Defensin HNP-3 human is abundant in human tongue squamous cell carcinoma and neutrophils infiltrating oral squamous cell carcinoma. Defensin HNP-3 human can be applied to research related to periodontitis and human tongue squamous cell carcinoma .

HY-145309

eIF4E-IN-3	Eukaryotic Initiation Factor (eIF)	Cancer
eIF4E-IN-3 (Example 485) is a eIF4E inhibitor with an IC₅₀ of 0.00859 μM. eIF4E-IN-3 inhibits the activity of eIF4E. eIF4E-IN-3 is used in cancer research .

HY-156730A

KT-333 ammonium	Molecular Glues STAT	Cancer
KT-333 ammonium (Compound A) is a molecular glues that degrades STAT3 protein. KT-333 ammonium mediates the selective degradation of STAT3 through the ubiquitin-proteasome system by binding to STAT3 protein and E3 ubiquitin ligase von Hippel-Lindau protein (VHL). KT-333 ammonium has strong selectivity for STAT3 protein degradation and good antitumor activity. KT-333 ammonium can be used in the study of hematologic malignancies such as large granular lymphocytic leukemia (LGL-L), peripheral T-cell lymphoma (PTCL), and cutaneous T-cell lymphoma (CTCL) .

HY-P5640

Tritrpticin	Bacterial Parasite	Infection
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against Trichomonas vaginalis, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .

HY-P990242

Anti-Mouse Galectin-9 Antibody (RG9-1)	Galectin TNF Receptor IFNAR Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 ⁺ and CD8 ⁺ T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .

HY-136522

S2116	Histone Demethylase Apoptosis	Cancer
S2116, a N-alkylated tranylcypromine (TCP) derivative, is a potent lysine-specific demethylase 1 (LSD1) inhibitor. S2116 increases H3K9 methylation and reciprocal H3K27 deacetylation at super-enhancer regions. S2116 induces apoptosis in TCP-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells by repressing transcription of the NOTCH3 and TAL1 genes. S2116 significantly retardes the growth of T-ALL cells in xenotransplanted mice .

HY-162676

SJ45566	PROTACs Src	Cancer
SJ45566 a potent and orally active PROTAC-based LCK degrader, with a DC₅₀ of 1.21 nM. SJ45566 can be used in the research for T‑Cell Acute Lymphoblastic Leukemia .

HY-175281

SJ11646	PROTACs Src Discoidin Domain Receptor Bcr-Abl Apoptosis	Cancer
SJ11646 is a Dasatinib (HY-10181)-based LCK PROTAC degrader with a DC₅₀ of 0.00838 pM. SJ11646 has potent cytotoxicity against LCK-activated T-cell acute lymphoblastic leukemia (T-ALL) cells and primary leukemia samples with drastically prolonged suppression of LCK signaling, and induces T-ALL apoptosis. SJ11646 binds to 51 human kinases with a high affinity (particularly ABL1, KIT, and DDR1). SJ11646 has superior antileukemic efficacy in T-ALL mice model. . Pink: LCK ligand (HY-107447); Blue: CRBN ligase ligand (HY-163169); Black: linker (HY-76667)

HY-P991543

BTI-322	CD2	Inflammation/Immunology Cancer
BTI-322 is a human IgG1κ antibody directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .

HY-175280

Lck degrader-1	Molecular Glues Src	Cancer
Lck degrader-1 (Compound 17) is a molecular glue degrader targeting lymphocyte-specific protein tyrosine kinase (LCK) (DC₅₀=23.1 nM). Lck degrader-1 is promising for research of T-cell acute lymphoblastic leukemia (T-ALL) .

HY-164466

CAD204520	Calcium Channel Notch	Cancer
CAD204520, a SERCA inhibitor (IC₅₀ = 0.34 μM), targets mutated over wild type NOTCH1 proteins in T-cell acute lymphoblastic leukemia (T-ALL) and mantle cell lymphoma (MCL). CAD204520 can be used for T-ALL and MCL research .

HY-P990115

Anti-Mouse OX40/CD134 Antibody (OX-86)	Orexin Receptor (OX Receptor)	Inflammation/Immunology Cancer
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonal antibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 ⁺ T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .

HY-P990803

Anti-Mouse CD28 Antibody (PV-1)	CD28	Inflammation/Immunology Cancer
Anti-Mouse CD28 Antibody (PV-1) is an anti-mouse CD28 IgG monoclonal antibody. Anti-Mouse CD28 Antibody (PV-1) can activate T cells. Anti-Mouse CD28 Antibody (PV-1) can be used for researches on cancer and immunology such as leukemia. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305) .

HY-B0971A

Pheniramine Prophenpyridamine; Tripoton; Pheniramine solution	Histamine Receptor Apoptosis	Inflammation/Immunology Cancer
Pheniramine (Prophenpyridamine;Tripoton) is a first-generation histamine H1 receptor antagonist, acts on the central nervous system (CNS) with sedative and hypnotic effect. Pheniramine displays antitumor effect and induces leukemia cells apoptosis. Pheniramine is also a safe and effective local agent that can suppress or relieve pain, with antipruritic effects .

Cat. No.	Product Name	Target	Research Area

HY-P11288

ANT308	PACAP Receptor Apoptosis	Cancer
ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P11288A

ANT308 TFA	PACAP Receptor Apoptosis	Cancer
ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .

HY-P2302

Defensin HNP-3 human	Antibiotic Bacterial Fungal	Infection Inflammation/Immunology Cancer
Defensin HNP-3 human is an α-defensin stored in the azurophilic granules of human neutrophils. Defensin HNP-3 human exerts broad-spectrum bactericidal, antifungal and antiviral activities mainly by forming bacterial membrane pores, and acts as a chemoattractant for monocytes and T cells. Defensin HNP-3 human maintains epithelial integrity to support periodontal tissue homeostasis, and exerts concentration-dependent effects on epithelial cell proliferation, adhesion and bacterial adhesion. Defensin HNP-3 human targets solid tumors and leukemia by inducing single-strand DNA breaks and membrane permeabilization in tumor cells via electrostatic binding and pore formation. Defensin HNP-3 human is abundant in human tongue squamous cell carcinoma and neutrophils infiltrating oral squamous cell carcinoma. Defensin HNP-3 human can be applied to research related to periodontitis and human tongue squamous cell carcinoma .

HY-P5640

Tritrpticin	Bacterial Parasite	Infection
Tritrpticin is a porcine-derived antimicrobial peptide with properties such as membrane disruption and hemolysis. Tritrpticin disrupts the cell membranes of bacteria, fungi and Jurkat T cell leukemia cells and induces their death. Tritrpticin also enhances the efficacy of Metronidazole (HY-B0318) against Trichomonas vaginalis, reduces plasma endotoxin and inflammatory cytokine levels, restricts bacterial growth in blood and visceral tissues, decreases the mortality rate of septic shock in rats and enhances the therapeutic effect of ertapenem. Tritrpticin exhibits selective cytotoxicity against Jurkat T cell leukemia cells, while showing low toxicity to normal peripheral blood mononuclear cells and red blood cells, and can serve as a template for antimicrobial peptide design. Tritrpticin can be applied to research related to bacterial infections, fungal infections, trichomoniasis, septic shock and leukemia .

HY-P10371

PKHB1 txCD47	Reactive Oxygen Species (ROS) Thrombopoietin Receptor Mitochondrial Metabolism HSP HSV CD47	Infection Inflammation/Immunology Cancer
PKHB1 (txCD47) is a CD47 agonist and Thrombospondin-1 peptide mimetic. PKHB1 activates CD47 and triggers Caspase-independent, calcium-dependent cell death via mitochondrial alterations, ROS production, endoplasmic reticulum morphological changes, and dissipation of mitochondrial membrane potential. PKHB1 induces the exposure of Calreticulin, HSP70, and HSP90, thereby driving immunogenic cell death. PKHB1 promotes intratumoral CD8 ⁺T cell infiltration and inhibits breast tumorigenesis. PKHB1 reduces HSV-1 levels and alleviates the severity of herpes simplex keratitis. PKHB1 can be used in research related to breast cancer, herpes simplex keratitis, and T-cell acute lymphoblastic leukemia .

HY-P10466A

KZR-8445 TFA	Sec61 SARS-CoV Interleukin Related TNF Receptor IFNAR	Infection Inflammation/Immunology
KZR-8445 TFA, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 TFA binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 TFA inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 TFA inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 TFA blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 TFA can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection .

HY-P10466

KZR-8445	Sec61 SARS-CoV Interleukin Related TNF Receptor IFNAR	Infection Inflammation/Immunology
KZR-8445, a cyclic depsipeptide, is a client-selective Sec61 inhibitor. KZR-8445 binds to the fully opened Sec61 lateral gate, blocks lumenal plug domain access, stabilizes lateral gate helices, traps select signal peptides, and disrupts secretory and membrane protein biogenesis. KZR-8445 inhibits pro-inflammatory cytokine secretion in primary immune cells. KZR-8445 inhibits SARS-CoV-2 replication, virus-induced cytotoxicity, and spike protein biogenesis. KZR-8445 blocks disease progression in a mouse model of rheumatoid arthritis. KZR-8445 can be used for the researches of rheumatoid arthritis and SARS-CoV-2 infection .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9963

Blinatumomab 2 Publications Verification bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO	CD19	Cancer
Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .

HY-P99014

Cusatuzumab 1 Publications Verification ARGX-110	Fc Receptor (FcR) NF-κB	Inflammation/Immunology Cancer
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML) .

HY-P99521

Vibecotamab XmAb14045	CD3	Inflammation/Immunology Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99910

Eluvixtamab AMG-330	CD3 Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Eluvixtamab (AMG-330) is a bispecific T-cell engager. Eluvixtamab binds to CD33 and CD3 on T cells, thereby promoting T cell-mediated cytotoxicity against CD33+ cells. Eluvixtamab can be used in the research of tumors such as relapsed/refractory acute myeloid leukemia .

HY-P99253

Mogamulizumab 1 Publications Verification KW-0761	CCR	Inflammation/Immunology Cancer
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb). Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) .

HY-P99916

Emirodatamab AMG-427	FLT3 CD3 TNF Receptor	Inflammation/Immunology Cancer
Emirodatamab (AMG-427) is a bispecific T-cell engager (BiTE). Emirodatamab simultaneously binds FLT3 on the surface of *acute myeloid leukemia* (AML)** cells and CD3 on the surface of T cells, thereby precisely recruiting immune effector cells to tumor sites. Emirodatamab potently induces T cell activation, secretion of proinflammatory cytokines (such as IFNγ, TNFα), and specific cytotoxicity, effectively lysing FLT3-positive tumor cells and inhibiting their growth. Emirodatamab not only significantly prolongs survival in mouse xenograft models and eliminates diseased cells in primates, but also exhibits a synergistic enhancement effect when combined with PD-1 blockade therapy. Emirodatamab is used in studies of acute myeloid leukemia, especially relapsed or refractory cases .

HY-P99914

Emfizatamab GNC-038	PD-1/PD-L1 CD19 TNF Receptor CD3 Interleukin Related IFNAR	Inflammation/Immunology Cancer
Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia .

HY-P990242

Anti-Mouse Galectin-9 Antibody (RG9-1)	Galectin TNF Receptor IFNAR Interleukin Related	Inflammation/Immunology Cancer
Anti-Mouse Galectin-9 Antibody (RG9-1) is an anti-mouse Galectin-9 IgG2b monoclonal antibody. Anti-Mouse Galectin-9 Antibody (RG9-1) promotes inflammatory response by enhancing the secretion of IFN-γ, TNF-α, and IL-6. Anti-Mouse Galectin-9 Antibody (RG9-1) can increase CD8 T cell and Treg frequency. Anti-Mouse Galectin-9 Antibody (RG9-1) reduces graft survival time by increasing CD4 ⁺ and CD8 ⁺ T cell infiltration. Anti-Mouse Galectin-9 Antibody (RG9-1) can be used for researches on inflammation conditions, cancer and xenotransplantation such as ischemia-reperfusion, colon cancer, breast cancer and leukemia .

HY-P991543

BTI-322	CD2	Inflammation/Immunology Cancer
BTI-322 is a human IgG1κ antibody directed against the CD2 antigen on T cells and NK cells. BTI-322 can block primary and memory alloantigen proliferative responses in vitro. BTI-322 recognizes over 90% of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias. BTI-322 has immunosuppressive activity. BTI-322 effectively inhibits T cell responses in vitro to allogeneic cells. BTI-322 can be used as a T-cell deplting agent. BTI-322 can be studied in research for renal allograft rejection and steroid-refractory acute graft-versus-host disease .

HY-P990115

Anti-Mouse OX40/CD134 Antibody (OX-86)	Orexin Receptor (OX Receptor)	Inflammation/Immunology Cancer
Anti-Mouse OX40/CD134 Antibody (OX-86) is an anti-mouse OX40/CD134 IgG1 monoclonal antibody. Anti-Mouse OX40/CD134 Antibody (OX-86) can enhance the anti-tumor function of CD8 ⁺ T cells. Anti-Mouse OX40/CD134 Antibody (OX-86) can reverse immune suppression, enhance antigen presentation and T cell activation. Anti-Mouse OX40/CD134 Antibody (OX-86) can be used for research on cancer such as papilloma and leukemia .

HY-P990803

Anti-Mouse CD28 Antibody (PV-1)	CD28	Inflammation/Immunology Cancer
Anti-Mouse CD28 Antibody (PV-1) is an anti-mouse CD28 IgG monoclonal antibody. Anti-Mouse CD28 Antibody (PV-1) can activate T cells. Anti-Mouse CD28 Antibody (PV-1) can be used for researches on cancer and immunology such as leukemia. The recommend isotype control of Anti-Mouse CD28 Antibody (PV-1): Armenian hamster IgG, Isotype Control (HY-P990305) .

HY-P990928

Mipletamig APVO-436	CD3 Interleukin Related	Inflammation/Immunology Cancer
Mipletamig (APVO-436) is a bispecific CD123 x CD3 monoclonal antibody. Mipletamig simultaneously binds to both CD3-expressing T cells and CD123-expressing cancer cells, thereby crosslinking CD123-expressing tumor cells and cytotoxic T lymphocytes (CTLs). This results in the activation and proliferation of T-cells and causes CTL-mediated cell lysis of CD123-expressing tumor cells. Mipletamig can be used for the study of acute myeloid leukemia (AML) .

HY-P990869

Anti-CD1a Antibody (OKT-6)	CD1 IFNAR Interleukin Related	Inflammation/Immunology Cancer
Anti-CD1a Antibody (OKT-6) is an anti-human CD1a IgG1 monoclonal antibody. Anti-CD1a Antibody (OKT-6) blocks T cell activation by blocking CD1a function. Anti-CD1a Antibody (OKT-6) can reduce the production of IFN-γ. Anti-CD1a Antibody (OKT-6) can be used for researches on cancer and inflammation such as leukemia. The recommend isotype control of Anti-CD1a Antibody (OKT-6): Mouse IgG1 kappa, Isotype Control (HY-P99977) .

HY-P992275

Anti-Nicastrin Antibody (A5226A)	γ-secretase	Neurological Disease Cancer
Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease .

HY-P992351

ELB021	Inhibitory Antibodies	Infection Cancer
ELB021 is an antibody inhibitor targeting the CD160 checkpoint. ELB021 specifically binds to CD160 on the cell surface and blocks its immune checkpoint pathway, thereby stimulating innate and adaptive anti-tumor immune responses. ELB021 effectively eliminates CD160-expressing cancer cells by enhancing T cell proliferation and CD8 ⁺ T cell-mediated cytotoxicity. Independent of PD-1 regulation, ELB021 is applicable to research related to B-cell leukemia and HIV-1 infection .

HY-P991896

AT1412 AT14-012	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
AT1412 is a CD9-binding antibody. AT1412 binds to the tetraspanin protein CD9 and modulates CD9 function by enhancing T cell adhesion to endothelial cells (HUVECs) and transendothelial migration. AT1412 binds to B-ALL cell lines but not to T-ALL. AT1412 induces antibody-dependent cellular cytotoxicity in B-ALL cell lines. AT1412 binds to melanoma cells, B-ALL, gastric cancer, colorectal cancer, and pancreatic cancer cells ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-19356

Rocaglamide 25+ Cited Publications Roc-A	Alkaloids Classification of Application Fields Other Alkaloids Plants Meliaceae Disease Research Fields Aglaia elliptifolia Source Classification Cancer	NF-κB HSP Eukaryotic Initiation Factor (eIF)
Rocaglamide (Roc-A) is isolated from the genus Aglaia and can be used for coughs, injuries, asthma and inflammatory skin diseases. Rocaglamide is a potent inhibitor of NF-κB activation in T-cells. Rocaglamide is a potent and selective heat shock factor 1 (HSF1) activation inhibitor with an IC₅₀ of ~50 nM. Rocaglamide inhibits the function of the translation initiation factor eIF4A. Rocaglamide also has anticancer properties in leukemia .

HY-W014118

α-Hexylcinnamaldehyde	Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Disease Research Fields Source Classification Cancer	Environmental Pollutants
α-Hexylcinnamaldehyde is an O-acetyltransferase (OAT) inhibitor. α-Hexylcinnamaldehyde inhibits OAT-mediated bioactivation of nitroarene mutagens, exerts antimutagenic activity through demutagenic and bioantimutagenic mechanisms, and interferes with ATP-binding cassette (ABC) transporter function to reduce substrate efflux. α-Hexylcinnamaldehyde alters membrane permeability, fluidizes phospholipid membranes, exerts antioxidant effects, and enhances the antiproliferative effect of Doxorubicin on human cancer cells. α-Hexylcinnamaldehyde can be used in the research of colorectal adenocarcinoma, T-cell leukemia, and multidrug-resistant cancers .

HY-W014118R

α-Hexylcinnamaldehyde (Standard)	Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Environmental Pollutants
α-Hexylcinnamaldehyde (Standard) is the analytical standard of α-Hexylcinnamaldehyde. This product is intended for research and analytical applications. α-Hexylcinnamaldehyde is an O-acetyltransferase (OAT) inhibitor. α-Hexylcinnamaldehyde inhibits OAT-mediated bioactivation of nitroarene mutagens, exerts antimutagenic activity through demutagenic and bioantimutagenic mechanisms, and interferes with ATP-binding cassette (ABC) transporter function to reduce substrate efflux. α-Hexylcinnamaldehyde alters membrane permeability, fluidizes phospholipid membranes, exerts antioxidant effects, and enhances the antiproliferative effect of Doxorubicin on human cancer cells. α-Hexylcinnamaldehyde can be used in the research of colorectal adenocarcinoma, T-cell leukemia, and multidrug-resistant cancers .

HY-N0990

1,5,15-Trimethylmorindol	Anthraquinones Morinda citrifolia Linn. Rubiaceae Plants Source Classification	Others
1,5,15-Trimethylmorindol is an anthraquinone isolated from the leaves of Morinda citrifolia. 1,5,15- trimethylmorindol (25 μg/mL) does not show significant cytotoxic activity on the human T-cell leukemia cell line, Jurkat, by itself but it shows cytotoxicity (IC₅₀ 14.5-15.0 μg/mL) when combined with 0.5-1.5 μg/mL of TRAIL in the cell proliferation assay .

Species:	Human (4) Cynomolgus (3)
Tag:	His (5) Avi (4) Fc (2)
Source:	HEK293 (6) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P70497

	CD7 Protein, Human (HEK293, His) T-cell Antigen CD7; GP40; T-cell leukemia Antigen; T-cell Surface Antigen Leu-9; TP41; CD7	Human	HEK293
	CD7 Protein, with an elusive function, interacts with SECTM1, implying involvement in SECTM1-related cellular processes. Further research is essential to uncover the specific functions and molecular pathways in which CD7 intricately participates. The current lack of detailed information emphasizes the ongoing exploration needed to elucidate CD7's functional significance and its interplay with SECTM1 in cellular contexts. CD7 Protein, Human (HEK293, His) is the recombinant human-derived CD7 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P72361

	CD7 Protein, Human (Biotinylated, HEK293, His-Avi) T-cell Antigen CD7; GP40; T-cell leukemia Antigen; T-cell Surface Antigen Leu-9; TP41	Human	HEK293
	CD7 Protein, with an elusive function, interacts with SECTM1, implying involvement in SECTM1-related cellular processes. Further research is essential to uncover the specific functions and molecular pathways in which CD7 intricately participates. The current lack of detailed information emphasizes the ongoing exploration needed to elucidate CD7's functional significance and its interplay with SECTM1 in cellular contexts. CD7 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD7 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.

HY-P705002

	CD7 Protein, Human (Biotinylated, HEK293, Fc-Avi) T-cell Antigen CD7; GP40; T-cell leukemia Antigen; T-cell Surface Antigen Leu-9; TP41	Human	HEK293

HY-P7808

	CD7 Protein, Cynomolgus (HEK293, His) rCynIg-like domain-containing protein/CD7, His; T-cell Antigen CD7; GP40; T-cell leukemia Antigen; T-cell Surface Antigen Leu-9; TP41; CD7	Cynomolgus	HEK293
	CD7 Protein is a 40-kDa membrane protein that belongs to the immunoglobulin superfamily. CD7 is mainly expressed in T cells and natural killer (NK) cells. CD7 plays a vital role in T and NK cell functions after binding to its ligands (K12 protein and galectin-1). CD7 plays an important role in T-cell and T-cell/B-cell interactions during early lymphoid development. CD7 is also invovled in T and NK cell activation and/or adhesion. CD7 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CD7 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P705189

	CD7 Protein, Cynomolgus (Biotinylated, HEK293, Fc-Avi) rCynIg-like domain-containing protein/CD7, His; T-cell Antigen CD7; GP40; T-cell leukemia Antigen; T-cell Surface Antigen Leu-9; TP41; CD7	Cynomolgus	HEK293

HY-P705190

	CD7 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) rCynIg-like domain-containing protein/CD7, His; T-cell Antigen CD7; GP40; T-cell leukemia Antigen; T-cell Surface Antigen Leu-9; TP41; CD7	Cynomolgus	HEK293

HY-P74530

	TCL1A Protein, Human (His) T-cell leukemia/lymphoma protein 1A; Oncogene TCL-1; TCL1A; TCL1	Human	E. coli
	TCL1A protein plays a crucial role in cell signaling by actively enhancing the phosphorylation and activation of AKT1, AKT2, and AKT3 while promoting the nuclear translocation of AKT1. Additionally, it aids cell proliferation, stabilizes mitochondrial membrane potential, and promotes cell survival. TCL1A Protein, Human (His) is the recombinant human-derived TCL1A protein, expressed by E. coli , with N-His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Host:	Mouse (2) Rabbit (3)
Reactivity:	Human (5) Rat (1) Mouse (1)
Application:	IHC-P (5) ICC/IF (4) WB (5) FC (2) ELISA (2)
Isotype:	IgG (3) IgG2a (2)
Conjugation:	Non-conjugated (5) Biotin (4)
Clonality:	Monoclonal (5) Recombinant (3)
Modification:	Unmodified (5)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P81660

	CD7 Antibody (YA1405) CD7; T-cell antigen CD7; GP40; T-cell leukemia antigen; T-cell surface antigen Leu-9; TP41; CD7	WB, IHC-P, ICC/IF, FC	Human
	CD7 Antibody (YA1405) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD7.

HY-P81660A

	CD7 Antibody (YA1405)(PBS only) CD7; T-cell antigen CD7; GP40; T-cell leukemia antigen; T-cell surface antigen Leu-9; TP41; CD7
	CD7 Antibody (YA1405) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CD7.

HY-P85928

	T Cell Leukemia/Lymphoma Protein 1A Antibody (YA5620) Anti TCL1A; Lymphoma/leukemia, T-cell; Oncogene TCL-1; Oncogene TCL1; P14 TCL1; P14 TCL1 protein; Protein p14 TCL1; T cell leukemia 1; T cell lymphoma 1; T cell lymphoma 1A; T-cell leukemia/lymphoma 1A; T-cell leukemia/lymphoma protein 1A; TCL 1 protein; TCL1; TCL1 oncogene; TCL1 PEN; Tcl1a; TCL1A; TCL1A_HUMAN	IHC-P, WB, ICC/IF, ELISA	Human
	T Cell Leukemia/Lymphoma Protein 1A Antibody (YA5620) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to T Cell Leukemia/Lymphoma Protein 1A.

HY-P85897

	CD7 Antibody (YA5589) CD7; CD7 antigen; p41; CD7 antigen; CD7 molecule; CD7_HUMAN; GP40; LEU 9; LEU9; p41 protein; T cell antigen CD7; T cell leukemia antigen; T cell surface antigen Leu 9; T-cell antigen CD7; T-cell leukemia antigen; T-cell surface antigen Leu-9; Tp 40; Tp40; TP41	IHC-P, WB, ICC/IF, ELISA	Human
	CD7 Antibody (YA5589) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to CD7.

HY-P81959

	T Cell Leukemia/Lymphoma Protein 1A Antibody (YA1704) Anti TCL1A; P14 TCL1; T cell leukemia 1; TCL1; TCL1 PEN; Tcl1a	WB, IHC-P, ICC/IF, FC	Human
	T Cell Leukemia/Lymphoma Protein 1A Antibody (YA1704) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to T Cell Leukemia/Lymphoma Protein 1A.

HY-P810353

	NOXA Antibody (YA9675) Adult T cell leukemia derived PMA responsive, APR, APR_HUMAN, ATL-derived, Immediate early response protein APR, Immediate-early-response protein APR, NOXA, Phorbol 12 myristate 13 acetate induced protein 1, Phorbol-12-myristate-13-acetate-induced protein 1, PMA induced protein 1	WB, IHC-P	Human, Mouse, Rat
	NOXA Antibody (YA9675) is a Rabbit-derived and non-conjugated IgG Recombinant,Monoclonal antibody, targeting to NOXA.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-153084A

CD19 CAR mRNA (Human) 1 Publications Verification		mRNA CAR-T
CD19 CAR mRNA (Human) expresses CAR protein that specifically targets human CD19. CD19 CAR mRNA can trigger transitory expression of CAR, allowing T cells to be targeted without permanent genetic modification. CD19 CAR mRNA targets CD19 which is a transmembrane glycoprotein primarily expressed on B lymphocytes and is important in B cell activation. CD19 CAR mRNA can be studied in cancer research such as lymphoma and leukemia .

HY-150725

ODN 1585		CpG ODNs
ODN 1585 is a potent inducer of IFN and TNFα production. ODN 1585 is a potent stimulator of NK (natural killer) function. ODN 1585 increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 induces regression of established melanomas in mice. ODN 1585 can confer complete protection against malaria in mice. ODN 1585 can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 can be used as a vaccine adjuvant .

HY-160041A

Olaptesed pegol sodium NOX-A12 sodium		Antisense Oligonucleotides
Olaptesed pegol (NOX-A12) sodium is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol sodium neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol sodium can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol sodium can be used for researches of colon cancer and lymphocytic leukemia .

HY-160041

Olaptesed pegol NOX-A12		Antisense Oligonucleotides
Olaptesed pegol (NOX-A12) is a L-oligoribonucleotide aptamer targeting CXCL12 based on a pegylated structure. Olaptesed pegol neutralizes CXCL12, and CXCL12 inhibition mobilizes chronic lymphocytic leukemia cells into the circulation and prevents their homing into the protective microenvironment. Olaptesed pegol can enhances the infiltration of human primary T cells and NK cells and inhibit tumor growth companied with anti-PD-1 antibody. Olaptesed pegol can be used for researches of colon cancer and lymphocytic leukemia .

HY-150725C

ODN 1585 sodium		CpG ODNs
ODN 1585 sodium is a potent inducer of IFN and TNFα production. ODN 1585 sodium is a potent stimulator of NK (natural killer) function. ODN 1585 sodium increases CD8+ T-cell function, including the CD8+ T cell-mediated production of IFN-γ. ODN 1585 sodium induces regression of established melanomas in mice. ODN 1585 sodium can confer complete protection against malaria in mice. ODN 1585 sodium can be used for acute myelogenous leukemia (AML) and malaria research. ODN 1585 sodium can be used as a vaccine adjuvant .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

T-cell leukemia

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Antibodies

Oligonucleotides

Natural
Products